Skip to main content

Table 1 Patient characteristics and outcome

From: Soluble urokinase plasminogen activator receptor and lactate as prognostic biomarkers in patients presenting with non-specific chief complaints in the pre-hospital setting – the PRIUS-study

  

Total

Serious condition

Serious condition

   

present

not present

  

N = 414

n = 63 (15.2%)

n = 351 (84.8%)

  

n

Md (IQR)

(%)

n

Md (IQR)

(%)

n

Md (IQR)

(%)

Sex

Female

234

 

(56.5)

34

 

(54.0)

200

 

(57.0)

 

Male

180

 

(43.5)

29

 

(46.0)

151

 

(43.0)

Age

Md

 

82 (75–88)

  

85 (79–90)

  

81 (75–88)

 

Admitted

Yes

225

 

(54.3)

54

 

(85.7)

171

 

(48.7)

 

No

189

 

(45.7)

9

 

(14.3)

180

 

(51.3)

In-hospital LOS

  

2 (0–9)

  

8 (3–13)

  

1 (0–7)

 

CCI

  

2 (0–9)

  

1 (0–2)

  

1 (0–7)

 

24 h mortality

 

0

 

(0.0)

0

 

(0.0)

0

 

(0.0)

30 day mortality

 

17

 

(4.1)

6

 

(9.5)

11

 

(3.1)

  1. LOS: length of stay. CCI: Charlson comorbidity index;